Reading SERA? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track SERA free→Reading SERA? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track SERA free→QuarterlyIQ Insights · SERA
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On May 26, 2026, Jeffrey T. Elliott, a member of the Board of Directors (the “Board”) of Sera Prognostics, Inc. (the “Company”), notified the Company of his decision to resign from the Board effective as of June 4, 2026, the date of the Company’s Annual Stockholders Meeting (“Annual Meeting”). Mr. Elliott’s resignation was not as a result of any di…
Results of Operations and Financial Condition. On May 6, 2026, Sera Prognostics, Inc. issued a press release announcing its financial results for the first quarter ended March 31, 2026 and providing business highlights. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934,…
Results of Operations and Financial Condition. On March 18, 2026, Sera Prognostics, Inc. issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2025 and providing business highlights. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities…
Results of Operations and Financial Condition. On November 13, 2025, Sera Prognostics, Inc. issued a press release announcing its financial results for the third quarter ended September 30, 2025 and providing business highlights. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act…
Results of Operations and Financial Condition. On August 6, 2025, Sera Prognostics, Inc. issued a press release announcing its financial results for the second quarter ended June 30, 2025 and providing business highlights. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 193…
Results of Operations and Financial Condition. On May 7, 2025, Sera Prognostics, Inc. issued a press release announcing its financial results for the first quarter ended March 31, 2025 and providing business highlights. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934,…
Results of Operations and Financial Condition. On March 19, 2025, Sera Prognostics, Inc. issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2024 and providing business highlights. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities…
Entry into a Material Definitive Agreement. On February 10, 2025, Sera Prognostics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC, TD Securities (USA) LLC and William Blair & Company, L.L.C., as representatives of the several underwriters named therein (the “Underwriters”), relating to the issuance and sale in an underwritten public offering (the “Offering”) by the Company of 1,250,000 shares of Class A common stock, par value $0…
Other Events. Termination of “At-the-Market” Offering Prospectus Supplement Pursuant to that certain sales agreement, dated August 7, 2024 (the “Sales Agreement”), that Sera Prognostics, Inc. (the “Company”) entered into with TD Securities (USA) LLC (“TD Cowen”), the Company may offer and sell, from time to time, shares of its Class A common stock, par value $0.0001 per share (the “Class A Common Stock”) through TD Cowen, acting as agent, through an “at the market offering” as defined in Rule…
Other Information. Presentation of PRIME Study Results Overview On January 31, 2025, final results of the Company’s PRIME study were presented at the Society for Maternal Fetal Medicine (“SMFM”) 2025 Pregnancy Meeting, and will again be presented at a subsequent virtual R&D day session hosted by the Company and the principal investigator. The study achieved both of its co-primary endpoints, showing significant reductions in the neonatal morbidity and neonatal hospital stays among low-risk pat…
Results of Operations and Financial Condition. Estimated Cash Balance as of December 31, 2024 (unaudited) Sera Prognostics, Inc. (the “Company”) is providing the following financial information. As of December 31, 2024, the Company’s cash, cash equivalents and marketable securities were approximately $68.2 million (unaudited). The estimated cash, cash equivalents and marketable securities as of December 31, 2024 are preliminary and may change, and are based on information available to managem…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.